Published: May 10, 2021
Source: Corporate News Center
On the occasion of UTop Pharma’s fifteenth anniversary, the company’s founder announced the next phase of development through an internal strategic briefing: the implementation of a “Dual-Track Strategy”, aimed at driving growth through both pharmaceutical innovation and consumer healthcare. This strategy marks the company’s entry into a “focus and leap” period, laying a solid foundation for sustained innovation and market expansion.
The core of the “Dual-Track Strategy” lies in:
Pharmaceutical CDMO Track: Continuing to deepen capabilities in peptide drug contract development and manufacturing services, providing innovative drug companies with end-to-end solutions from intermediates to final formulations. High-quality, customizable production supports clients in accelerating clinical development and commercialization.
Consumer Healthcare Track: Expanding into medical aesthetics, functional skincare, and health consumer products, applying the company’s pharmaceutical-grade peptide and lyophilization technology to high-value consumer applications, meeting the increasing market demand for safe and effective raw materials.
“The Dual-Track Strategy reflects our forward-looking insight into market trends and will become a new engine of growth for the company.”
— Founder, UTop Pharma
As the foundation for strategy implementation, UTop Pharma will continue to strengthen its technological advantages:
Peptide CDMO Capabilities: Optimizing production processes, scaling manufacturing capacity, and reinforcing GMP standards and quality systems to provide globally traceable, controlled, and high-quality raw materials and formulations.
Consumer Healthcare Technology Translation: Maintaining purity and activity of raw materials while optimizing formulations for safe, stable, and effective performance in medical aesthetic and skincare products.
This technological extension ensures both product quality and sustainable competitive barriers across different business tracks.
To ensure effective execution of the Dual-Track Strategy, the company has initiated:
Organizational Optimization: Establishing dedicated divisions for Pharmaceutical CDMO and Consumer Healthcare, each responsible for R&D, manufacturing, marketing, and client engagement, forming clear accountability and efficient collaboration.
Market Expansion and Partnerships: Strengthening cooperation with innovative drug companies domestically and internationally on the CDMO track; actively engaging with leading aesthetic and functional skincare brands on the consumer track, ensuring seamless technology application and commercialization.
“Through precise management and strategic coordination, we aim to translate technological innovation directly into market value.”
— Chief Operating Officer, UTop Pharma
The Dual-Track Strategy will enable UTop Pharma to achieve the following in the coming years:
Consolidate its pharmaceutical CDMO business, becoming a trusted partner for innovative drug developers worldwide;
Expand high-value consumer healthcare business, achieving diversified revenue streams;
Build an organization capable of balancing technological leadership with market agility, preparing for the company’s “focus and leap” phase.
The announcement also signals a clear long-term vision and sustainable growth strategy to the industry and investors.
In 2021, UTop Pharma is embarking on a new phase of development. By implementing the Dual-Track Strategy, the company will maintain its leadership in pharmaceutical technology while actively expanding into consumer healthcare, delivering diversified, high-quality peptide solutions to global clients.
UTop Pharma will continue to uphold “technology-driven, value-creating” principles, driving sustained breakthroughs in China’s peptide industry across pharmaceuticals and health consumer markets.
Issued by: Strategic Development Center
Editor: Corporate Branding Department
Date of Publication: May 10, 2021
